Published on
On Nov. 22, Professor Erika Lietzan traveled to Washington, D.C. to participate in a “Biopharma Roundtable” hosted by the Center for Intellectual Property x Innovation Policy (C-IP2) at the George Mason University Antonin Scalia Law School. This small invitation-only roundtable brought together a group of experts in economics and business, health policy and management, and intellectual property, as well as representatives of industry, and others, to discuss biopharmaceutical intellectual property policy issues, recent scholarship on those issues, and gaps in the scholarship.
Professor Lietzan is a senior scholar with C-IP2 and currently also serves as a distinguished commentator for the Center’s Thomas Edison Innovation Law and Policy Fellowship program, a year-long non-resident program in which fellows, with several rounds of collaboration with and advice from expert senior scholars, develop rigorous and substantial academic research papers on intellectual property law issues.